Business Context and Reporting Period
This Form 8-K Current Report from Adial Pharmaceuticals, Inc. (ADIL) covers events occurring on October 13, 2022, specifically the Company's 2022 Annual Meeting of Stockholders. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and equity plan amendments. It does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes and Corporate Actions
- Director Elections: Stockholders re-elected William B. Stilley, III and Kevin Schuyler as Class I directors for three-year terms expiring in 2025.
- Equity Plan Amendment: Stockholders approved Amendment No. 4 to the 2017 Equity Incentive Plan, increasing the authorized share pool by 2,000,000 shares, from 7,500,000 to 9,500,000 shares.
- Auditor Ratification: Stockholders ratified the appointment of Marcum, LLP as the independent registered public accounting firm for the year ending December 31, 2022.
Voting Results Summary
| Proposal | Votes For | Votes Against | Abstentions / Withheld | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (W.B. Stilley, III) | 6,320,847 | - | 1,635,805 (Withheld) | 6,934,207 |
| Election of Directors (Kevin Schuyler) | 5,568,541 | - | 2,388,111 (Withheld) | 6,934,207 |
| Ratification of Auditor (Marcum, LLP) | 14,729,500 | 120,288 | 41,071 | - |
| Equity Plan Amendment (Proposal 3) | 5,538,971 | 2,398,173 | 19,508 | 6,934,207 |
Guidance, Outlook, and Risks
This filing contains no management commentary regarding financial guidance, future outlook, specific risks, or contingencies. It strictly reports on the outcomes of the Annual Meeting proposals.
Key Facts for Investor Verification
- Verify the impact of the 2,000,000 share increase in the equity incentive plan on potential future dilution.
- Note the significant number of broker non-votes (6,934,207) on director elections and the equity plan amendment, indicating shares held in street name where brokers lacked discretionary voting power.
- Review the Definitive Proxy Statement (filed September 1, 2022) for detailed terms of the amended Equity Incentive Plan.
- Confirm the re-election of directors for terms extending through the 2025 Annual Meeting.